Literature DB >> 15156899

Recurrent peptic ulcers in patients following successful Helicobacter pylori eradication: a multicenter study of 4940 patients.

Hiroto Miwa1, Nobuhiro Sakaki, Kentaro Sugano, Hitoshi Sekine, Kazuhide Higuchi, Naomi Uemura, Mototsugu Kato, Kazunari Murakami, Chieko Kato, Akiko Shiotani, Toshifumi Ohkusa, Atsushi Takagi, Nobuo Aoyama, Ken Haruma, Kazuichi Okazaki, Kazuo Kusugami, Masayuki Suzuki, Takashi Joh, Takeshi Azuma, Akinori Yanaka, Hidekazu Suzuki, Hiroshi Hashimoto, Takashi Kawai, Toshiro Sugiyama.   

Abstract

OBJECTIVE: Although curative treatment of Helicobacter pylori infection markedly reduces the relapse of peptic ulcers, the details of the ulcers that do recur is not well characterized. The aim of this study is to describe the recurrence rate and specific features of peptic ulcers after cure of H. pylori infection.
METHODS: This was a multicenter study involving 4940 peptic ulcer patients who were H. pylori negative after successful eradication treatment and were followed for up to 48 months. The annual incidence of ulcer relapse in H. pylori-cured patients, background of patients with relapsed ulcers, time to relapse, ulcer size, and site of relapsed ulcers were investigated.
RESULTS: Crude peptic ulcer recurrence rate was 3.02% (149/4940). The annual recurrence rates of gastric, duodenal and gastroduodenal ulcer were 2.3%, 1.6%, and 1.6%, respectively. Exclusion of patients who took NSAIDs led annual recurrence rates to 1.9%, 1.5% and 1.3%, respectively. The recurrence rate was significantly higher in gastric ulcer. Recurrence rates of patients who smoked, consumed alcohol, and used NSAIDs were significantly higher in those with gastric ulcer recurrence compared to duodenal ulcer recurrence (e.g. 125 of 149 [83.9%] relapsed ulcers recurred at the same or adjacent sites as the previous ulcers).
CONCLUSIONS: Curative treatment of H. pylori infection is useful in preventing ulcer recurrence. Gastric ulcer is more likely to relapse than duodenal ulcer. Recurrent ulcer tended to recur at the site of the original ulcers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15156899     DOI: 10.1111/j.1083-4389.2004.00194.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  24 in total

1.  Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains.

Authors:  Li-Hui Wang; Hong Cheng; Fu-Lian Hu; Jiang Li
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

Review 2.  Severe and refractory peptic ulcer disease: the diagnostic dilemma: case report and comprehensive review.

Authors:  James L Guzzo; Mona Duncan; Barbara L Bass; Grant V Bochicchio; Lena M Napolitano
Journal:  Dig Dis Sci       Date:  2005-11       Impact factor: 3.199

Review 3.  Precise role of H pylori in duodenal ulceration.

Authors:  Michael Hobsley; Frank I Tovey; John Holton
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

Review 4.  Risk factors for gastrointestinal complications in aspirin users: review of clinical and experimental data.

Authors:  Felix W Leung
Journal:  Dig Dis Sci       Date:  2008-02-28       Impact factor: 3.199

5.  Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study.

Authors:  Hideki Mori; Hidekazu Suzuki; Juntaro Matsuzaki; Hitoshi Tsugawa; Seiichiro Fukuhara; Sawako Miyoshi; Kenro Hirata; Takashi Seino; Misako Matsushita; Toshihiro Nishizawa; Tatsuhiro Masaoka; Takanori Kanai
Journal:  United European Gastroenterol J       Date:  2015-11-13       Impact factor: 4.623

6.  Rebamipide reduces recurrence of experimental gastric ulcers: role of free radicals and neutrophils.

Authors:  Kazushi Sakurai; Toshihiro Osaka; Katsuya Yamasaki
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

7.  Population-based strategies for Helicobacter pylori-associated disease management: a Japanese perspective.

Authors:  Seiji Shiota; Kazunari Murakami; Toshio Fujioka; Yoshio Yamaoka
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2010-04       Impact factor: 3.869

8.  In vitro bactericidal activity of Jinghua Weikang Capsule and its individual herb Chenopodium ambrosioides L. against antibiotic-resistant Helicobacter pylori.

Authors:  Wei Liu; Yu Liu; Xue-Zhi Zhang; Ning Li; Hong Cheng
Journal:  Chin J Integr Med       Date:  2012-12-29       Impact factor: 1.978

9.  Evidence-based clinical practice guidelines for peptic ulcer disease 2015.

Authors:  Kiichi Satoh; Junji Yoshino; Taiji Akamatsu; Toshiyuki Itoh; Mototsugu Kato; Tomoari Kamada; Atsushi Takagi; Toshimi Chiba; Sachiyo Nomura; Yuji Mizokami; Kazunari Murakami; Choitsu Sakamoto; Hideyuki Hiraishi; Masao Ichinose; Naomi Uemura; Hidemi Goto; Takashi Joh; Hiroto Miwa; Kentaro Sugano; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2016-02-15       Impact factor: 7.527

10.  Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE--famotidine or rebamipide in comparison by endoscopy).

Authors:  Jun-ichi Yamao; Eiryo Kikuchi; Masami Matsumoto; Masaki Nakayama; Tatsuichi Ann; Hideyuki Kojima; Akira Mitoro; Motoyuki Yoshida; Masaaki Yoshikawa; Hiroshi Yajima; Yoshizumi Miyauchi; Hiroshi Ono; Koichi Akiyama; Goro Sakurai; Yoshikazu Kinoshita; Ken Haruma; Yoshinori Takakura; Hiroshi Fukui
Journal:  J Gastroenterol       Date:  2007-02-06       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.